Navigation Links
Access Pharmaceuticals Launches MuGard Product Website
Date:9/15/2010

/product-programs/mugard/">MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments.  Characterized Up to 40% of all patients receiving chemotherapy develop moderate to severe mucositis, and almost all patients receiving radiation for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, visit www.MuGard.com.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional infor
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
(Date:7/13/2014)... 2014 A decreased ability to identify odors ... Alzheimer,s disease, while examinations of the eye could ... with Alzheimer,s, in the brain, according to the ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... the decreased ability to identify odors was significantly ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... known that HIV patients are at an increased risk of ... shows // aggressive antiretroviral therapy may help lower that risk. ... therapy was associated with a lower incidence of Kaposi sarcoma ... more than 7,300 patients infected with HIV and the data ...
... In a study published in Diabetes Care, March 2005, scientists ... ,Insulin sensitivity is the measure for the risk ... then he has a lower risk of heart problems. ... insulin to control blood sugar. As this happens the body ...
... and heart attack can be reduced for heart patients undergoing ... of an anti-clotting drug before the procedure is the answer.// ... catheter is threaded into an artery. The balloon is inflated ... A small synthetic tube - stent is used to hold ...
... is known to help in controlling obesity. A new study ... Obesity (2005) says that dietary calcium present in the yogurt ... in lipid utilization and decrease in lipogenesis. ... one group was put on balanced deficit diets and the ...
... standard treatment with levodopa can reduce the amount of ... fluctuations they experience during the day . ,For ... drug entacapone, which must be taken with every levodopa ... of the additional drugs were effective in reducing the ...
... being hailed by researchers for its ability to target cancer ... called ON01910 works by interfering with a molecule known as ... multiply. This molecule is found in higher numbers in cancerous ... have especially high amounts. ,The drug was tested ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: